Literature DB >> 23114698

Rational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination.

Vincent J Venditto1, Douglas S Watson, Michael Motion, David Montefiori, Francis C Szoka.   

Abstract

The inability to generate broadly neutralizing antibody (bnAb) responses to the membrane proximal external region (MPER) of HIV-1 gp41 using current vaccine strategies has hampered efforts to prevent the spread of HIV. To address this challenge, we investigated a novel hypothesis to help improve the anti-MPER antibody response. Guided by structural insights and the unique lipid reactivity of anti-MPER bnAbs, we considered whether amino acid side chain modifications that emulate hydrophilic phospholipid head groups could contribute to the generation of 2F5-like or 4E10-like neutralizing anti-MPER antibodies. To test this hypothesis, we generated a series of chemically modified MPER immunogens through derivatization of amino acid side chains with phosphate or nitrate groups. We evaluated the binding affinity of the chemically modified peptides to their cognate monoclonal antibodies, 2F5 and 4E10, using surface plasmon resonance. The modifications had little effect on binding to the antibodies and did not influence epitope secondary structure when presented in liposomes. We selected five of the chemically modified sequences to immunize rabbits and found that an immunogen containing both the 2F5 and 4E10 epitopes and a phosphorylated threonine at T676 elicited the highest anti-peptide IgG titers, although the high antipeptide titers did not confer higher neutralizing activity. These data indicate that side chain modifications adjacent to known neutralizing antibody epitopes are capable of eliciting antibody responses to the MPER but that these chemically modified gp41 epitopes do not induce neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23114698      PMCID: PMC3535774          DOI: 10.1128/CVI.00615-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  62 in total

1.  Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection.

Authors:  Saurabh Mehandru; Brigitta Vcelar; Terri Wrin; Gabriela Stiegler; Beda Joos; Hiroshi Mohri; Daniel Boden; Justin Galovich; Klara Tenner-Racz; Paul Racz; Mary Carrington; Christos Petropoulos; Hermann Katinger; Martin Markowitz
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

2.  In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

Authors:  Amapola Manrique; Peter Rusert; Beda Joos; Marek Fischer; Herbert Kuster; Christine Leemann; Barbara Niederöst; Rainer Weber; Gabriela Stiegler; Hermann Katinger; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

3.  Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state.

Authors:  Mikyung Kim; Zhisong Qiao; Jessica Yu; David Montefiori; Ellis L Reinherz
Journal:  Vaccine       Date:  2006-10-09       Impact factor: 3.641

4.  Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids.

Authors:  Varun Gauba; Jan Grünewald; Vanessa Gorney; Lisa M Deaton; Mingchao Kang; Badry Bursulaya; Weijia Ou; Richard A Lerner; Christian Schmedt; Bernhard H Geierstanger; Peter G Schultz; Teresa Ramirez-Montagut
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

5.  Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.

Authors:  Johannes F Scheid; Hugo Mouquet; Beatrix Ueberheide; Ron Diskin; Florian Klein; Thiago Y K Oliveira; John Pietzsch; David Fenyo; Alexander Abadir; Klara Velinzon; Arlene Hurley; Sunnie Myung; Farid Boulad; Pascal Poignard; Dennis R Burton; Florencia Pereyra; David D Ho; Bruce D Walker; Michael S Seaman; Pamela J Bjorkman; Brian T Chait; Michel C Nussenzweig
Journal:  Science       Date:  2011-07-14       Impact factor: 47.728

6.  Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice.

Authors:  Douglas S Watson; Virginia M Platt; Limin Cao; Vincent J Venditto; Francis C Szoka
Journal:  Clin Vaccine Immunol       Date:  2010-12-15

7.  Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.

Authors:  Mansun Law; Rosa M F Cardoso; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

8.  Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites.

Authors:  Bruce K Brown; Nicos Karasavvas; Zoltan Beck; Gary R Matyas; Deborah L Birx; Victoria R Polonis; Carl R Alving
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

9.  Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.

Authors:  Ling Ye; Zhiyuan Wen; Ke Dong; Xi Wang; Zhigao Bu; Huizhong Zhang; Richard W Compans; Chinglai Yang
Journal:  PLoS One       Date:  2011-05-19       Impact factor: 3.240

10.  Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41.

Authors:  Douglas S Watson; Francis C Szoka
Journal:  Vaccine       Date:  2009-06-09       Impact factor: 3.641

View more
  10 in total

1.  The Atomic Structure of the HIV-1 gp41 Transmembrane Domain and Its Connection to the Immunogenic Membrane-proximal External Region.

Authors:  Beatriz Apellániz; Edurne Rujas; Soraya Serrano; Koldo Morante; Kouhei Tsumoto; Jose M M Caaveiro; M Ángeles Jiménez; José L Nieva
Journal:  J Biol Chem       Date:  2015-03-18       Impact factor: 5.157

Review 2.  Vaccine nanoparticles for protection against HIV infection.

Authors:  Marisa E Aikins; Joseph Bazzill; James J Moon
Journal:  Nanomedicine (Lond)       Date:  2017-02-21       Impact factor: 5.307

3.  Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.

Authors:  Melissa C Hanson; Wuhbet Abraham; Monica P Crespo; Stephanie H Chen; Haipeng Liu; Greg Lee Szeto; Mikyung Kim; Ellis L Reinherz; Darrell J Irvine
Journal:  Vaccine       Date:  2015-01-02       Impact factor: 3.641

4.  Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency.

Authors:  Cindy X Cai; Nicole A Doria-Rose; Nicole A Schneck; Vera B Ivleva; Brad Tippett; William R Shadrick; Sarah O'Connell; Jonathan W Cooper; Zachary Schneiderman; Baoshan Zhang; Daniel B Gowetski; Daniel Blackstock; Jacob Demirji; Bob C Lin; Jason Gorman; Tracy Liu; Yile Li; Adrian B McDermott; Peter D Kwong; Kevin Carlton; Jason G Gall; Q Paula Lei
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

5.  Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.

Authors:  Vincent J Venditto; Lindsay Wieczorek; Sebastian Molnar; Fernando Teque; Gary Landucci; Douglas S Watson; Donald Forthal; Victoria R Polonis; Jay A Levy; Francis C Szoka
Journal:  Clin Vaccine Immunol       Date:  2014-05-28

6.  Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.

Authors:  Saikat Banerjee; Heliang Shi; Habtom H Habte; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2016-01-21       Impact factor: 3.616

7.  Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.

Authors:  Habtom H Habte; Saikat Banerjee; Heliang Shi; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2015-10-09       Impact factor: 3.616

8.  An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice.

Authors:  Shuai Shao; Wei-Chiao Huang; Cuiyan Lin; Mark D Hicar; Celia C LaBranche; David C Montefiori; Jonathan F Lovell
Journal:  Ann Biomed Eng       Date:  2019-12-12       Impact factor: 3.934

9.  Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals.

Authors:  Luis M Molinos-Albert; Jorge Carrillo; Marta Curriu; Maria L Rodriguez de la Concepción; Silvia Marfil; Elisabet García; Bonaventura Clotet; Julià Blanco
Journal:  Retrovirology       Date:  2014-06-07       Impact factor: 4.602

10.  DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity.

Authors:  Lara Ajamian; Luca Melnychuk; Patrick Jean-Pierre; Gerasimos J Zaharatos
Journal:  Viruses       Date:  2018-02-27       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.